In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Strategy Business Strategies

Collaborating for Better R&D Productivity

Executive Summary

Pooling multiple pharmaceutical companies' assets across a given therapeutic area will allow industry to make rational R&D investment decisions, expedite resource allocation and reduce investment in also-rans, eventually boosting productivity and improving a worsening reimbursement environment. Oncology may be a smart place to begin.

You may also be interested in...



In A First, Merck And AstraZeneca Team Up For Oncology Study

The two Big Pharmas have allied for early development of Merck’s AKT inhibitor and AZ’s Mek inhibitor. But where do they go from there?

Best of the Blog: IN VIVO, May/June 2009

Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.

Best of the Blog: IN VIVO, May/June 2009

Our favorite blog posts related to stories not covered elsewhere in this month's IN VIVO.

Table

View full table

Related Content

In Vivo
In Vivo
In Vivo
In Vivo

Topics

Related Companies

Related Deals

Tags:
BioPharmaceutical Strategy Business Strategies
Latest Headlines

The Clinical Trial Accessibility Checklist: How Does Your Organization Measure Up?

Deals in Depth August 2023

Snapshot: August Highlights

Execs On The Move: August 2023

See All
UsernamePublicRestriction

Register

IV003252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By